Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epidermal growth factor receptor (EGFR)
Pharma
Dizal takes on J&J with first-line win in EGFR lung cancer type
Dizal is proposing its oral drug Zegfrovy as a monotherapy, while J&J's injection Rybrevant is used alongside chemo in first-line EGFR exon 20 NSCLC.
Angus Liu
May 29, 2026 8:00am
Akeso details ivonescimab's 1st overall survival win
Nov 7, 2025 11:30am
AZ offers early look at Datroway-Tagrisso combo in lung cancer
Mar 19, 2025 7:05pm
J&J's Rybrevant-Lazcluze tops AZ's Tagrisso on overall survival
Jan 7, 2025 8:00am
Despite J&J's full nod, FDA endorses Dizal's accelerated plan
Jun 26, 2024 11:08am
J&J's Rybrevant moves into first line in lung cancer subtype
Mar 4, 2024 11:13am
